Kyverna Therapeutics, Inc. Common Stock - Asset Resilience Ratio
Kyverna Therapeutics, Inc. Common Stock (KYTX) has an Asset Resilience Ratio of 73.19% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Kyverna Therapeutics, Inc. Common Stock (KYTX) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Kyverna Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. See Kyverna Therapeutics, Inc. Common Stock (KYTX) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Kyverna Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see KYTX market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $136.97 Million | 73.19% |
| Total Liquid Assets | $136.97 Million | 73.19% |
Asset Resilience Insights
- Very High Liquidity: Kyverna Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 73.19% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kyverna Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Kyverna Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Kyverna Therapeutics, Inc. Common Stock (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Kyverna Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 62.16% | $189.36 Million | $304.64 Million | +31.71pp |
| 2023-12-31 | 30.45% | $22.90 Million | $75.19 Million | +10.15pp |
| 2022-12-31 | 20.30% | $13.59 Million | $66.92 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $85.49 Million | -- |
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also develo… Read more